Verastem, Inc. Stock News

Verastem plans to raise $250 million as it prepares for late-stage testing of its experimental cancer treatment.

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers, today announced the pricing of an underwritten offering of 30,937,500 shares of its common stock at an offering price of $8.00 per share, and in lieu of common s...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that Michael P. Bailey has been appointed President and Chief Executive Officer (CEO), effective January 1, 2027. Mr. Bailey will also continue to serve on the Company's Board of Directors. The CEO transiti...

BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--VS-7375 demonstrates robust clinical activity with favorable safety and tolerability in KRAS G12D-mutated pancreatic, lung and colorectal cancers.

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 380,500 restricted stock units (RSUs) to 24 new employees and stock options to purchase 50,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq ind...

BOSTON--(BUSINESS WIRE)---- $VSTM #CancerResearch--New RAMP 201 Molecular Profiling and External Control Arm Analyses Supports Outcomes for Avutometinib Plus Defactinib in Recurrent LGSOC.

BOSTON--(BUSINESS WIRE)---- $VSTM #CancerResearch--Long-term RAMP 201 results published in Gynecologic Oncology reinforce durable clinical benefit and manageable safety profile in recurrent LGSOC.

BOSTON--(BUSINESS WIRE)---- $VSTM #CancerResearch--Verastem to present late-breaking oral presentation of RAMP 201 LGSOC molecular profiling and tumor biomarker analysis at IGCS 2026.